BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category

BRAF-AXL-PD-L1 Signaling Axis as a Possible Biological Marker for RAI Treatment in the Thyroid Cancer ATA Intermediate Risk Category

The use of radioiodine therapy (RIT) is debated in intermediate-risk differentiated thyroid cancer (DTC) patients. The understanding of the molecular mechanisms involved in the pathogenesis of DTC can be useful to refine patient selection for RIT. We analyzed the mutational status of BRAF, RAS, TERT...

Full description

Bibliographic Details
Main Authors: Cristina Pizzimenti, Vincenzo Fiorentino, Antonio Ieni, Esther Diana Rossi, Emanuela Germanà, Luca Giovanella, Maria Lentini, Ylenia Alessi, Giovanni Tuccari, Alfredo Campennì, Maurizio Martini, Guido Fadda
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:International Journal of Molecular Sciences
Subjects:
thyroid cancer
BRAF mutation
PD-L1 expression
AXL expression
Online Access:https://www.mdpi.com/1422-0067/24/12/10024

Internet

https://www.mdpi.com/1422-0067/24/12/10024

Similar Items